-
81
-
82
A High Rate of Return to Running Is Seen After Both Arthroscopic and Open Shoulder Surgery
Published 2023-10-01Get full text
Article -
83
-
84
Rare variant analyses across multiethnic cohorts identify novel genes for refractive error
Published 2023-01-01Get full text
Article -
85
-
86
Scleral Buckling for Primary Retinal Detachment: Outcomes of Scleral Tunnels versus Scleral Sutures
Published 2021-07-01Get full text
Article -
87
Unexpected Selective Gas Adsorption on a ‘Non-Porous’ Metal Organic Framework
Published 2020-06-01Get full text
Article -
88
-
89
-
90
Elevated rates of horizontal gene transfer in the industrialized human microbiome
Published 2022Get full text
Article -
91
A missense variant in human perilipin 2 (PLIN2 Ser251Pro) reduces hepatic steatosis in mice
Published 2024-01-01Get full text
Article -
92
Optimal Treatment of Proximal Humeral Fractures in the Elderly: Risks and Management Challenges
Published 2023-06-01Get full text
Article -
93
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents
Published 2023-11-01“…Joseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J Singerman,1 Richard Donkor,1 Margaret Fink,1 Ryan Zubricky,4 Helene Karcher2 1Retina Associates of Cleveland Inc, Beachwood, OH, USA; 2Novartis Pharma AG, Basel, Switzerland; 3KMK Consulting, Morristown, NJ, USA; 4Geisinger Eye Institute, Danville, PA, USACorrespondence: Joseph M Coney, Retina Associates of Cleveland Inc, 24075 Commerce Park, Beachwood, OH, 44122, USA, Tel +1 (216) 831-5700, Email jconey@retina-assoc.comObjective: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alternating with another anti-VEGF.Methods: The overall study population comprised eyes that were given ≥ 1 brolucizumab injection between 1 October 2019 and 30 November 2021. …”
Get full text
Article -
94
-
95
-
96
-
97
Evaluation of the US COVID-19 Scenario Modeling Hub for informing pandemic response under uncertainty
Published 2023-11-01Get full text
Article -
98
-
99
Capgras syndrome conceptualization: from a delusional disorder to a structural neurological phenomenon
Published 2023-03-01Get full text
Article -
100